Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer
Key Points
Key Points
- Multiple studies of both chemotherapy and endocrine therapy have shown that neoadjuvant treatment can increase the likelihood of breast-conserving surgery.
- The CTNeoBC pooled analysis of neoadjuvant breast cancer clinical trials published in 2014 confirmed that achievement of a pathologic complete response (pCR) with neoadjuvant treatment was prognostic.
- It also showed that the association between pCR and outcomes was strongest in patients with triple negative and human epidermal growth factor receptor 2 (HER2)-positive disease.
- Optimal therapy for breast cancer is driven by subtype.
Treatment
...eatment
...Recommendation from 2022 Guideline Rapid R...
...ith T1cN1-2 or T2-4N0 (stage II or III), earl...
...andidates...
...emotherapy is the treatment of choice for patie...
..., grade, stage and estrogen, progesterone...
...ant systemic therapy should be offe...
...oadjuvant systemic therapy may be offered...
...ients for whom a delay in surgery is pref...
Measuring Response
...ring Respons...
...ing neoadjuvant therapy should be monit...
...nd tissue-based biomarkers should no...
...fined as absence of invasive disease in...
Recommended Regimens for Patients with TNBC
...gimens for Patients with TNBC...
...with TNBC who have clinically node positive and/...
...h cT1a or cT1bN0 TNBC should not rout...
Carboplatin may be offered as part o...
...insufficient evidence to recommend routinel...
Recommended Neoadjuvant Treatment for Patients with HER2-negative/HR-positive Breast Cancer
...nded Neoadjuvant Treatment for Patient...
...nt chemotherapy can be used instead of adju...
...usal patients with HR+, HER2-negative disease,...
...al patients with HR+, HER2-negative early-stage di...
Recommended Neoadjuvant Treatment for Patients with HER2-Positive Disease
...adjuvant Treatment for Patients with HER2-...
...atients with node-positive or high-r...
...nts with T1a N0 and T1b N0, HER2+ disease shou...